US 12,433,857 B2
Conjugate and cancer therapeutic agent
Nobuhiro Nishiyama, Tokyo (JP); Takahiro Nomoto, Tokyo (JP); Kana Kohmoto, Tokyo (JP); Hiroyasu Takemoto, Tokyo (JP); and Makoto Matsui, Tokyo (JP)
Assigned to TOKYO INSTITUTE OF TECHNOLOGY, Tokyo (JP); and SBI PHARMACEUTICALS CO., LTD., Tokyo (JP)
Appl. No. 17/605,027
Filed by Tokyo Institute of Technology, Tokyo (JP); and SBI Pharmaceuticals Co., Ltd., Tokyo (JP)
PCT Filed Apr. 23, 2020, PCT No. PCT/JP2020/017421
§ 371(c)(1), (2) Date Oct. 20, 2021,
PCT Pub. No. WO2020/218390, PCT Pub. Date Oct. 29, 2020.
Claims priority of application No. 2019-083250 (JP), filed on Apr. 24, 2019.
Prior Publication US 2022/0211646 A1, Jul. 7, 2022
Int. Cl. A61K 31/16 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01)
CPC A61K 31/16 (2013.01) [A61K 47/64 (2017.08); A61P 35/00 (2018.01); A61K 47/645 (2017.08)] 3 Claims
OG exemplary drawing
 
1. A mixed drug comprising ascorbic acid and a conjugate in which a deferoxamine-type compound, which is at least one compound selected from the group consisting of deferoxamine or an ion or salt thereof, and a derivative thereof, and a biocompatible polymer are conjugated,
wherein the biocompatible polymer contains a first biocompatible polymer chain and a second biocompatible polymer chain that is different from the first biocompatible polymer chain,
wherein the second biocompatible polymer chain is a polyamino acid,
the first biocompatible polymer chain is polyethylene glycol, and
the conjugate includes a structure having Formula (1):
A-L-B   (1)
wherein A represents the first biocompatible polymer chain; L represents a linker part; and B represents the second biocompatible polymer chain, and
wherein the conjugate includes a structure having Formula (1-2):

OG Complex Work Unit Chemistry
wherein 1 is an integer of 1 to 1,500, B represents the second biocompatible polymer chain and includes a repeating structure represented by formula (b2-1), or a repeating structure represented by formula (b1-1) and a repeating structure represented by formula (b2-1),

OG Complex Work Unit Chemistry
wherein R11 represents an amino acid side chain; R12 is a group obtained by conjugating a carboxyl group in an aspartic acid side chain represented by —CH2—COOH or a carboxyl group in a glutamic acid side chain represented by —CH2—CH2—COOH to the deferoxamine-type compound; and n1 represents the total number of (b1-1) and (b2-1) structures, n1 is an integer of 1 to 1,000, m1 is an integer of 1 to 1,000, m1≤n1, when n1−m1 is 2 or more, a plurality of R11's may be the same as or different from each other, and when m1 is 2 or more, a plurality of R12's may be the same as or different from each other.